49th week of 2012 patent applcation highlights part 55 |
Patent application number | Title | Published |
20120309761 | FAST-RESPONSE PHOTOCHROMIC NANOSTRUCTURED CONTACT LENSES - A bicontinuous microemulsion of water, a monomer, and a surfactant copolymerizable with the monomer is polymerized to form a polymeric material, the polymeric material comprising a polymer matrix defining interconnected pores. The polymeric material may additional comprise at least one photochromic agent. The photochromic agent may be dispersed in one or both of the polymer matrix or the interconnected pores. The polymeric material may be used to form photochromic articles including ophthalmic articles such as contact lenses. | 2012-12-06 |
20120309762 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF - The present invention features compounds of formula I | 2012-12-06 |
20120309763 | ANTIFUNGAL COMPOSITION INTENDED TO BE APPLIED TO A PERFORATED NAIL - A pharmaceutical composition intended to be applied to a perforated nail is described. In particular, a composition is descirbed that includes an antifungal agent that is in the form of an acid salt, advantageously a hydrochloride; and a solvent system; and advantageously a cationic or positively charged amphoteric surfactant. The described composition can have a viscosity of less than 500 cPs. | 2012-12-06 |
20120309764 | Heteroaromatic aryl triazole derivatives as PDE10A enzyme inhibitors - This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. | 2012-12-06 |
20120309765 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE - The invention relates to a method of inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal comprising administering to said mammal a therapeutically effective amount of an imidazopyridine of formula I with anti-hyperproliferative activity. | 2012-12-06 |
20120309766 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS - The invention relates to compounds of formula (I) | 2012-12-06 |
20120309767 | PROCESS FOR THE PREPARATION OF ALPHA FORM OF IMATINIB MESYLATE - The present invention provides an improved process for the preparation of alpha form of imatinib mesylate with (long needle) and α-crystal form (small needle) in a consistent manner and novel alpha crystal forms of imatinib mesylate. The present invention in particular provides a reproducible and efficient process. In particular the present invention provides a efficient process which gives higher yields and consistent results. | 2012-12-06 |
20120309768 | NOVEL TUBULIN POLYMERISATION INHIBITORS - The present invention relates to compounds of general formula (I) as tublin polymerisation inhibitors and methods for preparing such compounds. | 2012-12-06 |
20120309769 | N-BENZYLINDOLE MODULATORS OF PPARG - The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), and inhibit kinase-mediated (e.g., cdk5-mediated) phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. Side effects such as significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, can be avoided in the mammal receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided. | 2012-12-06 |
20120309770 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2012-12-06 |
20120309771 | NOVEL ANTIFUNGAL TRIAZOLE DERIVATIVES - Disclosed are novel triazole derivatives. Exhibiting excellent antifungal activity and in vivo safety, they are useful for the treatment or prevention of fungal infections caused by a wide spectrum of fungi. | 2012-12-06 |
20120309772 | INHIBITORS OF FATTY ACID UPTAKE AND METHODS OF USE - The present disclosure describes inhibitors of fatty acid uptake and methods of using such inhibitors. Specifically, the present disclosure describes inhibitors with specificity for FATP2. | 2012-12-06 |
20120309773 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS - The invention provides compounds of formula I: | 2012-12-06 |
20120309774 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS - The present invention provides compounds of formulae Ia and Ib: | 2012-12-06 |
20120309775 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS - The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), | 2012-12-06 |
20120309776 | PYRROLO[2,3-D]PYRIMIDINE UREA COMPOUNDS AS JAK INHIBITORS - The present invention provides pyrrolo{2,3-d}pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds. | 2012-12-06 |
20120309777 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS - Compounds of formula (I): wherein R | 2012-12-06 |
20120309778 | Fused and Spirocycle Compounds and the Use Thereof - The invention relates to fused and spirocycle compounds of Formula (I), or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R | 2012-12-06 |
20120309780 | MICELLE COMPOSITION OF POLYMER AND PASSENGER DRUG - Hydrophobic drugs become more practical for treatments by being encapsulated in micelle compositions for increasing solubility. Micelle compositions may include an excipient tocopherol and/or prodrug formulations of the drug. Micelles extend the time period the drug remains in the micelles to improve drug circulation time and thereby drug delivery. Hydrophobic drugs for micelle encapsulation may include rapamycin, geldanamycin, and paclitaxel. Administration of these micelle compositions does not require Cremophor EL or Tween 80, avoiding serious side effects associated with these products which would previously accompany such drug administration. | 2012-12-06 |
20120309781 | TETRAHYDRO-beta-CARBOLINE DERIVATIVES, SYNTHESIS AND USE THEREOF - Certain 2-halophenyl, 2,4-dihalophenyl (e.g. 2,4-dichlorophenyl), 3,4-dichlorophenyl (e.g. 3,4-dichlorophenyl), 2,6-dichlorophenyl (2,6-dichlorophenyl) and 2,5-diakoxyphenyl (e.g. 2,5-dimethoxyphenyl) derivatives of tetrahydro-β-carbolines are provided, along with their pharmaceutically acceptable salts; prodrugs and solvates, and compositions containing the compounds. The compounds are useful for the prevention and treatment of cancer, and other indications where PDE5 inhibitors have shown benefits including erectile dysfunction, pulmonary hypertension, enhancing cognitive function, cystic fibrosis, or enhancing the activity of conventional chemotherapeutic drugs. Methods for fabricating the compounds are also provided. | 2012-12-06 |
20120309782 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS - Disclosed herein are compounds represented by the structural formula: | 2012-12-06 |
20120309783 | KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE - Compounds that inhibit protein kinases such as Aurora-kinases and the VEGFR and PDGFR families of kinases, with an improved safety profile due to low CYP3A4 inhibition, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. | 2012-12-06 |
20120309784 | TRIAZOLOPYRIDINE KINASE INHIBITORS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES - A novel [1,2,4]triazolo[1,5-a]pyridine compound is disclosed that has a formula represented by the following: | 2012-12-06 |
20120309785 | Use of Cysteamine in Treating Parkinson's Disease - The subject invention provides materials and methods for treating neurodegenerative diseases. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat Parkinson's Disease and/or complications associated with Parkinson's Disease. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of Parkinson's Disease in an at-risk patient and/or treat or prevent the onset of Parkinson's Disease-associated symptoms. | 2012-12-06 |
20120309786 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS - Compounds represented by the general formula (I): | 2012-12-06 |
20120309787 | INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS AND USES THEREOF - The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions. | 2012-12-06 |
20120309788 | Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases - The present invention relates to a method for treating an individual having Alzheimer's Disease by using pharmacological chaperones to increase the activity of gangliosidase and/or sialidase enzymes involved in ganglioside catabolism. | 2012-12-06 |
20120309789 | Compounds which have activity at M1 receptor and their uses in medicine - Compounds of general formula | 2012-12-06 |
20120309790 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS - A treatment for a dermatological allergic condition is disclosed, using a compound of Formula I: | 2012-12-06 |
20120309791 | NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS - The present invention relates to novel compounds of formula (II) that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating, or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed | 2012-12-06 |
20120309792 | TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS - This invention relates to novel tetrazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 2012-12-06 |
20120309793 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES - The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) | 2012-12-06 |
20120309794 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS - The present invention concerns compounds, some of which are novel, and their pharmaceutical applications. The compounds of the invention inhibit the enzyme lactate dehydrogenase (LDH) involved both in the metabolic process of hypoxic tumour cells, and in the process used by parasitic protozoa that cause malaria to obtain most of the energy they need. | 2012-12-06 |
20120309795 | HETEROCYCLIC INHIBITORS OF NECROPTOSIS - The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role. | 2012-12-06 |
20120309796 | BENZOCYCLOHEPTENE ACETIC ACIDS - Provided herein are compounds of the formula (I): | 2012-12-06 |
20120309797 | PYRIDYL CYANOGUANIDINE DERIVATIVES - Compounds of formula (I) or pharmaceutically acceptable salts thereof, and use for treating cancer thereof are disclosed, wherein, the definitions of X, Y, R | 2012-12-06 |
20120309798 | Tumour Treatment Agents and Method - N1-(3-Methoxypropyl)-2-(pyridylmethylidene)-hydrazine-1-carbothioamide (I) and its Cu | 2012-12-06 |
20120309799 | BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT - A biguanide derivative compound with N4-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK and inhibition of cancer cell proliferation in a low dose, compared with conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc. | 2012-12-06 |
20120309800 | METALLOENZYME INHIBITOR COMPOUNDS - The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes. | 2012-12-06 |
20120309801 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING - A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described. | 2012-12-06 |
20120309802 | ESTER COMPOUND AND USE THEREOF - An ester compound represented by formula (1):
| 2012-12-06 |
20120309803 | ESTER COMPOUND AND USE THEREOF - An ester compound represented by formula (1): | 2012-12-06 |
20120309804 | COMPOSITIONS AND METHODS FOR TREATMENT OF GLAUCOMA - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine. | 2012-12-06 |
20120309805 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID - The invention provides a crystalline freebase form of 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension. | 2012-12-06 |
20120309806 | Process for the Sulfinylation of a Pyrazole Derivative - The present invention relates to a process for the of a pyrazole derivative, characterized in that 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonitrile (II) is reacted with a sulfinylating agent selected from trifluoromethylsulfinic acid, trifluoromethylsulfinic acid anhydride, and a trifluoromethylsulfinate alkaline or alkaline earth metal salt and mixtures of the acid and/or the salt(s), in the presence of at least one amine acid complex wherein the amine(s) are selected from tertiary amines and the acid(s) are selected from hydrofluoric, hydrochloric, hydrobromic and hydroiodic acid and sulfonic acid derivatives, and with the addition of a halogenating agent. | 2012-12-06 |
20120309807 | METHODS AND COMPOSITIONS RELATED TO REGULATION OF CYTOKINE PRODUCTION BY GLYCOGEN SYNTHASE KINASE 3 (GSK-3) - This invention relates generally to a method of treating inflammation and associated diseases and disorders by administering an agent that inhibits glycogen synthase kinase 3 activity. | 2012-12-06 |
20120309808 | COMPOSITIONS AND METHODS FOR EPIGENETIC MODIFICATION OF NUCLEIC ACID SEQUENCES - Provided herein are pharmaceutical compositions and methods for treating disorders characterized by reduced expression of anti-oxidative stress enzymes in a subject. In one aspect, the present invention provides a method for inducing expression of anti-oxidative stress enzymes in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of a demethylating agent. The demethylating agent includes a phytochemical that induces expression of Nrf2 and Nrf2-mediated genes expressing anti-oxidative stress. Such phytochemicals include indoles, such as 3,3′-diindolylmethane (DIM) and indole-3-carbinol (I3C), and isothiocyanates, such as phenethyl isothiocyanate (PEITC) and sulforaphane (SFN). | 2012-12-06 |
20120309809 | PROCESS AND PRODUCT - A method of processing an active ingredient, the method comprising submitting a pharmaceutically active ingredient in the absence of excipients and/or additives to compression and shearing forces. The invention also relates to compositions comprising an active prepared by the method. | 2012-12-06 |
20120309810 | TREATMENT OF ATRIAL FIBRILLATION - Atrial fibrillation (AF) can be treated or prevented by administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent, which is | 2012-12-06 |
20120309811 | P-GLYCOPROTEIN-SPECIFIC NON-COMPETITIVE PEPTIDE AND PEPTIDOMIMETIC MODULATORS - The invention relates to a compound having structure (I), which acts as a non-competitive specific inhibitor of P-glycoprotein (P-gp for “Pleiotropic glycoprotein”) and which can be used as a drug, particularly for improving the effectiveness of chemotherapy treatments. The invention is therefore suitable for use in the medical field, particularly for the chemotherapeutic treatment of cancers or infections. | 2012-12-06 |
20120309812 | INSECTICIDAL COMPOUNDS - The present invention relates to certain bisamide derivatives of formula (I), to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests compounds. | 2012-12-06 |
20120309813 | DELIVERY OF dsRNA TO ARTHROPODS - The invention is to methods of gene silencing in arthropods using dsRNA. The method is include contacting the arthropod with, and/or directly feeding the arthropod, the dsRNA to the arthropods to deliver the dsRNA to arthropod tissues. It is envisaged that the methods of the invention will have use in determining the biological function of genes in arthropods. Methods of pest control of arthropods, and of protecting arthropods against parasites and predators are provided. Transgenic arthropods expressing dsRNA molecules are also provided by the present invention. | 2012-12-06 |
20120309814 | TREATMENT OF PYRROLINE-5-CARBOXYLATE REDUCTASE 1 (PYCR1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO PYCR1 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Pyrroline- | 2012-12-06 |
20120309815 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF OLIGONUCLEOTIDES - The present invention relates to compositions and methods which enhance the delivery of nucleic acids and other nucleosidic moieties via topical routes of administration. The invention relates to the use of an aqueous solution to preferentially deliver nucleic acids preferentially to hair follicles. The invention relates to a method of inhibiting hair growth comprising administration of a nucleic acid preferentially to a hair follicle. | 2012-12-06 |
20120309816 | Novel viral vector construct for neuron specific optimized continuous DOPA synthesis in vivo - The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof. | 2012-12-06 |
20120309817 | VIRAL AND NON-VIRAL VECTORS AS VEHICLES FOR DELIVERING TRANSGENES FOR TREATING BONE PATHOLOGIES - The present invention relates to a method for treating bone pathologies comprising delivering a viral or non-viral delivery vehicle comprising genetic information (e.g. a transgene) encoding a therapeutic osteoinductive factor to target cells in vivo enabling the cells to produce the osteoinductive factor at the site of the bone pathology. The delivery is achieved by a simplified method which does not require cumbersome ex vivo techniques or additional matrix or scaffolding agents. Such viral and non-viral delivery vehicles of the present invention are derived from the following nonlimiting examples: adenoviruses, adeno-associated viruses, retroviruses, herpes simplex viruses, liposomes, and plasmids. The osteoinductive factors include, but are not limited to, growth factors, cytokines, growth factor inhibitors and cytokine inhibitors. | 2012-12-06 |
20120309818 | CHRONIC INFLAMMATION AND TRANSPLANTATION - Embodiments of the present invention feature methods for treating inflammatory disease and transplantation characterized in that it includes: (i) the incubation of organs with one or more Bryostatin-1 derivatives under conditions which permits vascular exposure to these compounds prior to or immediately following organ ‘harvesting’, and (ii) intravenous, transdermal, intraperitoneal, intra-alveolar instillation of Bryostatin-1 in vivo during active disease, or during periods of disease remission and (iii) prophylactic administration of Bryostatin-1 to limit the development of GVHD. | 2012-12-06 |
20120309819 | Acid-Labile Lipophilic Prodrugs of Cancer Chemotherapeutic Agents - The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof. | 2012-12-06 |
20120309820 | METHODS OF TREATING FIBROTIC DISEASES USING TETRAHYDROCANNABINOL-11-OIC ACIDS - This invention is in the field of medicinal chemistry and relates to novel compounds, and pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring/wound healing abnormalities, post operative adhesions, and reactive fibrosis. The invention also relates to methods of using the compounds and pharmaceutical compositions of this invention to treat fibrotic conditions. | 2012-12-06 |
20120309821 | Use of epigallocatechin-3-gallate for immune regulation - The preset invention relates to a method for treating lupus erythematosus, particularly lupus nephritis, comprising administering a subject in need thereof a therapeutically effective amount of epigallocatechin-3-gallate (EGCG) or a pharmaceutically acceptable salt or a physiologically functional derivative, together with one or more pharmaceutically acceptable carriers, diluents or excipients. | 2012-12-06 |
20120309822 | TREATMENT OF INFECTIOUS DISEASES - The present invention relates to the treatment or prevention of infectious disorders, and to tonabersat or an analogue of formula (1), and compositions comprising tonabersat or an analogue of formula (1) for use in said treatments. | 2012-12-06 |
20120309823 | PERCUTANEOUS ABSORPTION PREPARATIONS - Percutaneous absorption preparations which make it possible to absorb compounds having a melatonin receptor agonist activity via a convenient administration system, have favorable blood-drug-concentration-time profile and can exert a therapeutic effect on a disease caused by a decrease in secretion of melatonin at night. | 2012-12-06 |
20120309824 | AZEOTROPIC AND AZEOTROPE-LIKE COMPOSITIONS OF E-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE AND ETHYLENE OXIDE AND USES THEREOF - Azeotropic or azeotrope-like compositions are disclosed. The azeotropic or azeotrope-like compositions are mixtures of E-1,1,1,4,4,4-hexafluoro-2-butene and ethylene oxide. Also disclosed are double azeotropic compositions of E-1,1,1,4,4,4-hexafluoro-2-butene and ethylene oxide. Also disclosed is a process of preparing a thermoplastic or thermoset foam by using such azeotropic or azeotrope-like compositions as blowing agents. Also disclosed is a process of producing refrigeration by using such azeotropic or azeotrope-like compositions. Also disclosed is a process of using such azeotropic or azeotrope-like compositions as solvents. Also disclosed is a process of producing an aerosol product by using such azeotropic or azeotrope-like compositions. Also disclosed is a process of using such azeotropic or azeotrope-like compositions as heat transfer media. Also disclosed is a process of extinguishing or suppressing a fire by using such azeotropic or azeotrope-like compositions. Also disclosed is a process of using such azeotropic or azeotrope-like compositions as dielectrics. Also disclosed is a method for sterilizing an article by using such azeotropic or azeotrope-like compositions. | 2012-12-06 |
20120309825 | Nitrate Esters And Their Use For The Treatment Of Muscle And Muscle Related Diseases - Alkyl nitrate ester compounds are provided for the delivery of nitric oxide to targeted muscle tissues, and in particular, to normal and dystrophic muscles. In one aspect, nitrate ester compounds are provided having the following formula: | 2012-12-06 |
20120309826 | STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE - The present invention provides a stabilized pharmaceutical suspension of carisbamate for pediatric and adult use. More particularly, the suspension is stabilized with hypromellose (HPMC) to prevent crystal growth of the suspended particles and to prevent re-crystallization of the drug product with change in polymorphic form. | 2012-12-06 |
20120309827 | THERAPEUTIC COMPOSITIONS - Ingenol angelate is a potent anticancer agent, and can be stabilised by dissolving it in an aprotic solvent in the presence of an acidic buffer. | 2012-12-06 |
20120309828 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF - The invention encompasses compositions and methods for treating or preventing kidney disease in a companion animal, wherein the compositions and methods include feeding the companion animal an edible composition including at least one pyruvate or salt thereof. | 2012-12-06 |
20120309829 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF - The invention encompasses compositions and methods for maintaining or promoting a healthy body composition in a companion animal, which comprises feeding the animal an edible composition comprising one or more pyruvate in an amount effective to maintain or promote the healthy body composition, wherein maintaining or promoting the healthy body composition comprises controlling the animal's weight, for example, loss of weight or body fat, or increased percentage of lean muscle mass. | 2012-12-06 |
20120309830 | MIXED FATTY ACID SOAP/FATTY ACID BASED INSECTICIDAL, CLEANING, AND ANTIMICROBIAL COMPOSITIONS - The present disclosure relates to compositions including a fatty acid soap/fatty acid mixture, and methods of use thereof. The compositions include a C5 to C12 fatty acid or mixtures thereof. The compositions show increased activity, e.g., insecticidal, soil removal, antimicrobial activity, at a controlled pH range of about 7.5 to about 9.0. | 2012-12-06 |
20120309831 | BALANCED FAT COMPOSITION AND USE THEREOF IN A LIQUID NUTRITIONAL COMPOSITION SUITABLE FOR ENTERAL FEEDING - This invention relates to a balanced fat composition and use thereof in a liquid nutritional composition, in particular suitable for tube feeding. This invention further relates to said liquid nutritional composition for providing enteral nutrition to patients in need thereof, in particular for providing a complete enteral nutrition, in particular for providing a long-term enteral nutrition. More specifically, the balanced fat composition and the liquid nutritional composition comprising said balanced fat composition comprises specific amounts of linoleic acid (LA), alpha-linolenic acid (ALA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), at least one medium chain fatty acid (MCFA), and at least one mono-unsaturated fatty acid (MUFA). The invention relates further to a method for providing enteral nutrition to patients in need thereof comprising administering an effective amount of said liquid nutritional composition comprising the balanced fat composition according to the invention. | 2012-12-06 |
20120309832 | Acetylcysteine Composition and Uses Thereof - This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent. | 2012-12-06 |
20120309833 | NOVEL BEXAROTENE ANALOGS - The present invention relates to analogs of bexarotene and methods of use thereof. | 2012-12-06 |
20120309834 | NOVEL USES OF ADIPIC ACID - The present invention relates to a method for preventing or treating obesity, diabetes, dyslipidemia, fatty liver or insulin resistance syndrome, comprising: administering to a mammalian subject in need thereof a therapeutically effective amount of a composition comprising adipic acid. The present composition containing adipic acid as an active ingredient is very effective in preventing or treating obesity, diabetes, dyslipidemia, fatty liver (preferably, non-alcoholic fatty liver) or insulin resistance syndrome. The composition of the present invention useful as pharmaceuticals compositions or functional food compositions has therapeutic efficacies for obesity, dyslipidemia or fatty liver, and also induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic diseases. | 2012-12-06 |
20120309835 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES - Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject. | 2012-12-06 |
20120309836 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF TRPV1 AGONISTS - Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions are also provided. | 2012-12-06 |
20120309837 | Bronchodilating Beta-Agonist Compositions and Methods - Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided. | 2012-12-06 |
20120309838 | USE OF AGOMELATINE IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD) - The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Obsessive-Compulsive Disorder (OCD). | 2012-12-06 |
20120309839 | DOSING REGIMES FOR TRANS-CLOMIPHENE - The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism and disorders related thereto, including reduction of muscle mass. limitation of body performance capacity, reduction of bone density, reduction of libido, reduction of potency, reduction of benign prostatic hyperplasia and infertility. | 2012-12-06 |
20120309840 | Treatment of Pain Associated with Trigeminal Neuralgia - The use of tapentadol for the treatment of pain associated with disorders of the trigeminal nerve, in particular for use in the treatment of pain associated with trigeminal neuralgia. | 2012-12-06 |
20120309841 | Method of Inhibiting Chronification of Pain - The use of tapentadol in the treatment of pain and/or pain chronification in a subject suffering from pain chronification and/or in the treatment of pain and inhibition of pain chronification in a subject suffering from pain and at risk of pain chronification, as well as the use of tapentadol for the treatment or inhibition of migraine. | 2012-12-06 |
20120309842 | PROCESSES FOR THE PREPARATION OF CINACALCET - The present invention provides processes and intermediates for preparing cinacalcet base and pharmaceutically acceptable salts thereof. | 2012-12-06 |
20120309843 | HIGHLY PERMEATING TERBINAFINE FORMULATION - The present invention provides topical compositions, methods of preparation, and methods of treatment for onychomychosis. In certain specific embodiments, the invention provides an anti-fungal pharmaceutical composition for topical application comprising an anti-fungal agent, a zwitterionic surfactant or charged derivative thereof; a carboxylic acid, a lower alcohol, and water. The acid is selected from a short-chain hydroxy acid, a short-chain fatty acid, and a mixture thereof. In certain other specific embodiments, the invention provides an anti-fungal pharmaceutical composition for topical application comprising an anti-fungal agent, a quarternary amino acid, a keratolytic agent; a lower alcohol; and water. In certain embodiments, the keratolytic agent is urea, ammonium thioglycolate, or a mixture thereof. | 2012-12-06 |
20120309844 | Substituted Diphenylamine Compounds, Preparation Method and Use Thereof - Substituted diphenylamine compounds of general formula I are provided, in which each substituted group is defined as in the description. The compounds of general formula I have broad-spectrum fungicidal activity in the field of agriculture. Furthermore, the preparation methods of the above compounds are simple. | 2012-12-06 |
20120309845 | DOSING REGIMENS AND METHODS FOR TREATING OR PREVENTING ACUTE MYELOID LEUKEMIA - The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating acute myeloid leukemia in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone. | 2012-12-06 |
20120309846 | DOSING REGIMENS AND METHODS FOR TREATING OR PREVENTING MYELODYSPLASTIC SYNDROME - The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating myelodysplastic syndrome in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone. | 2012-12-06 |
20120309847 | DOSING REGIMENS AND METHODS FOR TREATING OR PREVENTING PROMYELOCYTIC LEUKEMIA - The invention encompasses dosing regimens in which a subject is administered menatetrenone over a period of time to establish initial therapeutic baseline blood concentration of the menatetrenone followed by a maintenance therapy to maintain therapeutic blood concentrations. In other embodiments, the invention encompasses methods of treating promyelocytic leukemia in a subject in need thereof comprising administering to a subject a therapeutically effective dosing regimen of menatetrenone. | 2012-12-06 |
20120309848 | NOVEL USES OF NONENAL - The present invention relates to a method for preventing or treating dyslipidemia or fatty liver, comprising: administering to a mammalian subject in need thereof a therapeutically effective amount of a composition comprising nonenal. The present composition containing nonenal as an active ingredient is very effective in preventing or treating obesity, diabetes, dyslipidemia, fatty liver or insulin resistance syndrome (preferably, dyslipidemia or fatty liver, more preferably hyperlipidemia or fatty liver). The composition of the present invention useful as pharmaceuticals compositions or functional food compositions has therapeutic efficacies for obesity, diabetes, hyperlipidemia or fatty liver, and also induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic disorders. | 2012-12-06 |
20120309849 | USE OF GLYCERIN SHORT-CHAIN ALIPHATIC ETHER COMPOUNDS - A solvent or composition that includes a glycerin short-chain aliphatic ether may be used in a method for coupling, coalescing or adjusting viscosity of a composition. | 2012-12-06 |
20120309850 | WOUND CARE DEVICE - A wearable article formed of a gelatinous elastomer composition having 100 parts by weight of triblock copolymer of the general configuration poly(styrene-ethylene-butylene-styrene) wherein the styrene end block to ethylene and butylene center block ratio is within the range of from between 31:69 to 40:60, from about 300 to about 1,600 parts by weight of a plasticizing oil and having a gel rigidity of about 20 gram to about 700 gram Bloom. | 2012-12-06 |
20120309851 | Process for Reducing Residual Surface Material from Porous Polymers - The present invention relates to methods for removing residual surface material from porous polymerized particle surfaces. The particles thus produced have an increase in surface porosity and uniformity in a variety of applications. Desirably, substantially the entire surface communicates with the interior of the particles. Also provided are the particles produced by such methods, further modifications of such particles, and methods for using the particles in a variety of applications. All described methods, compositions, and articles of manufacture are within the scope of the invention. | 2012-12-06 |
20120309852 | Polylactide Hydrosol and Articles Made Therefrom - A polylactide hydrosol polymer formulations suitable for thin film articles and methods of making the thin film articles are provided. The formulations and methods can be use to make articles such as gloves, condoms, catheters and the like using dip forming, and various casting processes. | 2012-12-06 |
20120309853 | ALDOHEXOSE-BASED FLUOROADDITIVES - Compositions comprising compounds having an aldohexose moiety, a highly fluorinated moiety, and a nitrogen-containing functional group linking the moieties together are disclosed. The aldohexose-based fluoroadditives are effective in reducing the surface tension of water and are useful in various surfactant applications. Also disclosed are processes for making aldohexose-based fluoroadditives. | 2012-12-06 |
20120309854 | ALDOHEXOSE-BASED FLUOROADDITIVES - Compositions comprising compounds having an aldohexose moiety, a highly fluorinated moiety, and a nitrogen-containing functional group linking the moieties together are disclosed. The aldohexose-based fluoroadditives are effective in reducing the surface tension of water and are useful in various surfactant applications. Also disclosed are processes for making aldohexose-based fluoroadditives. | 2012-12-06 |
20120309855 | LOW CALORIE, NON-GRAIN, VEGAN TREATS FOR COMPANION ANIMALS - The invention provides methods of using hay, vegetable and/or fruit pulp, and a hydrocolloid for making animal food; and the food products produced using such methods; and the products then being dried through low-temperature dehydration. The animal food products are free of gluten, grains, legumes, nuts, animal-products, sweeteners, and fats. | 2012-12-06 |
20120309856 | METHOD OF PRODUCING A HYDROCARBON COMPOSITION - Method of producing a hydrocarbon composition in which a biomass raw-material is gasified to produce a raw syngas containing carbon monoxide, carbon dioxide and hydrogen, the hydrogen-to-carbon monoxide ratio being about 0.5 to 1.7. A part of the impurities is removed to produce a clean syngas which is fed into a Fischer-Tropsch reactor where a significant part of the carbon monoxide and hydrogen is converted to a hydrocarbon composition containing C | 2012-12-06 |
20120309857 | POLYARYLENE-BASED POLYMER, PREPARATION METHOD FOR THE SAME, AND POLYMER ELECTROLYTE MEMBRANE FOR FUEL CELL USING THE POLYMER - Disclosed herein is a polyarylene-based polymer, a preparation method for the same, and a polymer electrolyte membrane for fuel cell using the polymer. The polyarylene-based polymer, which is designed to have long side chains of a hydrophilic moiety and dense sulfonic acid groups, may improve the formation of ion channels when fabricating a polymer membrane and also ensures good chemical stability of the hydrophilic moiety and good dimensional stability against water. Further, the preparation method of the present invention simplifies production of the polymer, and polymer electrolyte membranes using the polymer exhibits improved properties as a polymer electrolyte membrane for a fuel cell, such as high proton conductivity, even under an atmosphere of low water uptake, and good dimensional stability against a long-term exposure to water. | 2012-12-06 |
20120309858 | METHOD FOR RECYCLING SYNTHETIC TURF AND PRODUCT - The invention comprises a composition comprising the extrusion product of synthetic turf and a processing agent, whereby the extrusion product has a moisture content of less than 0.5% by weight. A process for making the composition is also disclosed. | 2012-12-06 |
20120309859 | INTERPOLYMER RESIN PARTICLES - Interpolymer resin particles that include from about 20% to about 60% by weight based on the weight of the particles of uncross-linked polyolefin resin particles having a VICAT softening temperature greater than 85° C. and from about 40% to about 80% by weight based on the weight of the interpolymer particles of polymerized vinyl aromatic monomer composition particles that have been polymerized in the uncross-linked polyolefin resin particles to form an interpenetrating network of polyolefin resin particles and polystyrene particles. The interpolymer resin particles have a gel content ranging from about 0 to about 1.5% by weight based on the weight of the interpolymer resin particles, a VICAT softening temperature ranging from about 90° C. to about 115° C., and a melt index value ranging from about 0.2 to about 35.0 g/10 minutes (Condition G). | 2012-12-06 |
20120309860 | METHODS OF MAKING LITHIUM ION BATTERY SEPARATORS - A porous thin-film polymer separator for use in a lithium ion battery may be formed by a phase separation method in which hydrophobic-treated ceramic particles are used to help induce the formation of a tortuous, interconnected network of pores coextensively across the thickness of the separator. As part of the phase separation method, a wet thin-film layer is formed from a polymer slurry that comprises a polymer solvent in which a polymer material is dissolved and the hydrophobic-treated ceramic particles are dispersed. The wet thin-film layer is subsequently exposed to a polymer non-solvent to form a solvent-exchanged thin-film precipitated polymer layer which is then heated to produce the separator. | 2012-12-06 |
20120309861 | PHOTOINITIATORS FOR UV-LED CURABLE COMPOSITIONS AND INKS - A specific type of carbazole photoinitiator is capable of providing radiation curable compositions that are curable by UV LEDs and do not exhibit an unstable yellowing behaviour in an image upon storage like ITX. | 2012-12-06 |